- Home
- NDMO vs LAB Comparison
NDMO vs LAB Comparison
Compare NDMO & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDMO
- LAB
- Stock Information
- Founded
- NDMO 2019
- LAB 1999
- Country
- NDMO United States
- LAB United States
- Employees
- NDMO N/A
- LAB N/A
- Industry
- NDMO Trusts Except Educational Religious and Charitable
- LAB Biotechnology: Laboratory Analytical Instruments
- Sector
- NDMO Finance
- LAB Industrials
- Exchange
- NDMO Nasdaq
- LAB Nasdaq
- Market Cap
- NDMO 620.6M
- LAB 473.2M
- IPO Year
- NDMO N/A
- LAB 2011
- Fundamental
- Price
- NDMO $10.43
- LAB $1.35
- Analyst Decision
- NDMO
- LAB Buy
- Analyst Count
- NDMO 0
- LAB 2
- Target Price
- NDMO N/A
- LAB $2.50
- AVG Volume (30 Days)
- NDMO 218.6K
- LAB 1.2M
- Earning Date
- NDMO 01-01-0001
- LAB 10-29-2025
- Dividend Yield
- NDMO 6.75%
- LAB N/A
- EPS Growth
- NDMO N/A
- LAB N/A
- EPS
- NDMO N/A
- LAB N/A
- Revenue
- NDMO N/A
- LAB $172,271,000.00
- Revenue This Year
- NDMO N/A
- LAB N/A
- Revenue Next Year
- NDMO N/A
- LAB N/A
- P/E Ratio
- NDMO N/A
- LAB N/A
- Revenue Growth
- NDMO N/A
- LAB 76.33
- 52 Week Low
- NDMO $8.99
- LAB $0.92
- 52 Week High
- NDMO $11.24
- LAB $2.32
- Technical
- Relative Strength Index (RSI)
- NDMO 74.58
- LAB 56.33
- Support Level
- NDMO $10.36
- LAB $1.27
- Resistance Level
- NDMO $9.98
- LAB $1.41
- Average True Range (ATR)
- NDMO 0.12
- LAB 0.08
- MACD
- NDMO 0.05
- LAB 0.01
- Stochastic Oscillator
- NDMO 94.57
- LAB 73.81
About NDMO Nuveen Dynamic Municipal Opportunities Fund of Beneficial Interest
Nuveen Dynamic Municipal Opportunities is a closed-end management investment company. Its investment objective is to seek total return through income exempt from regular federal income taxes and capital appreciation. A majority of its investments are made in municipal securities, the income from which is exempted from regular federal income taxes.
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.